Clinical Trials

A parent-founded nonprofit is funding a landmark gene therapy trial, aiming to create the first-ever treatment for a rare neurodevelopmental disorder.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

A pivotal partnership between WeInfuse and Trial IQ leverages AI to bring clinical trials to local infusion centers, signaling a major shift in drug development.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

Early Phase 1 data for APR-1051 reveals anti-tumor activity and manageable safety, offering a new glimmer of hope for patients with advanced solid tumors.

A new drug targeting cancer's 'immortality switch' enters a pivotal trial, offering hope for non-small cell lung cancer patients out of options.

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

A new drug combination delays cancer progression by over a year in advanced prostate cancer, offering new hope against treatment resistance, a new study finds.

New long-term data on pegcetacoplan offers significant hope for patients with rare, debilitating kidney diseases, strengthening Sobi's market position.